Metabolic dysfunction-associated steatotic liver disease(MASLD)has become the most prevalent chronic liver disease worldwide,and China is facing a severe challenge of rapidly increasing MASLD burden.Beverages,as an important modifiable factor,have become a research focus for primary prevention and lifestyle management of MASLD.This article reviews beverage consumption trends,provides an in-depth analysis of the mechanisms and health effects of sugar-sweetened beverages,alcoholic drinks,coffee,and tea on MASLD,summarizes their potential pathogenic and protective pathways,and explores comprehensive strategies including beverage intervention,lifestyle coordination,functional beverage development,psychological and behavioral mechanism regulation,and targeted population prevention.The aim is to provide theoretical basis and practical guidance for the localized and precise prevention and control of MASLD.

Objective To observe the clinical effect of pioglitazone combined with gliclazide sustained-release tablets in the treatment of patients with early type 2 diabetes mellitus.Methods 80 patients with early type 2 diabetes mellitus in our hospital from June 2013 to July 2016 were selected as the study object,and the patients were randomly divided into two groups, 40 cases in each group.The control group were treated with gliclazide sustained-release tablets, the observation group were treated with pioglitazone combined with gliclazide sustained-release tablets.Then the blood glucose level, glycosylated hemoglobin level, lipid metabolism indexes and islet function indexes of two groups before and after the treatment were detected and compared.Results The blood glucose level, glycosylated hemoglobin level, lipid metabolism indexes and islet function indexes of two groups before the treatment were compared, the difference was statistically significant (P<0.05), while the blood glucose level, glycosylated hemoglobin level, lipid metabolism indexes and islet function indexes of two groups after the treatment were continuously improved , and the blood glucose level and glycosylated hemoglobin level of observation group were lower than those of control group, the ipid metabolism indexes and islet function indexes were all better than those of control group, the difference was statistically significant (P <0.05).Conclusion The clinical effect of pioglitazone combined with gliclazide sustained-release tablets in the treatment of patients with early type 2 diabetes mellitus is better, and it also has active adjustion role for the blood glucose, blood lipid and islet function state.